The CPHI Shanghai exhibition concluded successfully on June 18. EXTRABROC®—a stable, high-conversion sulforaphane ingredient recognized internationally for its superior technical capabilities—made a major appearance at the event. Engaging with domestic and international brands, contract manufacturers, and procurement professionals, the team provided technical insights, data consultation, compliance solutions, and sample discussions. The exhibit drew significant interest and garnered widespread acclaim from global clients.

I. Exhibition Highlights: Precisely Solving Three Core Industry Pain Points

EXTRABROC® achieves comprehensive technological breakthroughs to address common industry issues associated with traditional broccoli extracts, such as low conversion rates, lack of clinical support, poor stability, and weak patent protection. While ordinary glucoraphanin ingredients on the market offer conversion rates of only 5%–10%—resulting in minimal efficacy—this product utilizes a patented enzyme system to achieve a conversion rate of ≥55.8%. Independent of human gut microbiota and backed by authoritative clinical data, it delivers tangible, noticeable benefits that effectively boost repeat purchase rates for end products. Furthermore, the product is supported by over a dozen domestic and international clinical trials, peer-reviewed papers in authoritative journals, and application cases in top-tier hospitals; it fully meets rigorous overseas compliance standards, facilitating successful global market expansion for brands. Additionally, it overcomes the limitations of traditional ingredients—which often require cold-chain logistics and are prone to oxidation and degradation—by offering 24-month stability at room temperature. This significantly reduces supply chain costs (warehousing, logistics, etc.) and supports global distribution strategies, establishing it as a benchmark sulforaphane ingredient with high barriers to entry.

II. Four Core Advantages Building Unreplicable Technical Barriers

1. Ultra-high conversion, consistent efficacy: Third-party testing by CNAS confirms a conversion rate of ≥55.8%, effectively resolving issues regarding inconsistent performance or lack of efficacy found in traditional ingredients. A related human double-blind controlled study was published in the authoritative journal *Food & Function*, providing solid academic backing.

2. Long-lasting stability at room temperature: cost-effective and efficient: Validated against the 2025 edition of the *Pharmacopoeia of the People's Republic of China*, the product remains stable for 24 months at 25°C. Throughout this period, it retains over 90% of its glucoraphanin content and over 85% of its enzymatic activity. Eliminating the need for a cold chain significantly reduces cross-border distribution and supply chain costs.

3. Robust evidence and diverse applications: Backed by extensive, publicly accessible clinical research data from both domestic and international sources, the product’s findings have been incorporated into national dietary nutrient reference standards and expert consensus guidelines. It has been adopted by over 100 top-tier (Grade 3A) hospitals and is widely used in key sectors such as anti-aging, mood regulation, weight management, and sports nutrition.

4. Global compliance and patent protection: The product holds core authorized patents in China and Japan, with US patents currently in the substantive examination stage, creating a high barrier to imitation. It meets dual compliance standards—China’s "New Food Raw Materials" and US FDA GRAS—and holds international certifications including GMP, ISO22000, and HALAL, facilitating seamless market entry both domestically and abroad.

III. Exhibition Concludes; Setting Sail for the Shenzhen Expo

With the successful conclusion of the Shanghai exhibition, the brand remains committed to the precision nutrition sector, leveraging its unique technological advantages to rise above the industry's "race to the bottom" caused by homogenization. The brand will next appear at the CPHI Shenzhen exhibition, scheduled for September 16–18, 2026, at the Shenzhen Convention & Exhibition Center (Futian), Booth No. 7D-60. Industry partners are invited to request technical documentation, clinical data, and certification details, as well as to discuss sample testing and customized collaborations (Contact: Ms. Wang, 18255197575) to explore new opportunities in the global nutrition industry.